Journal of Clinical Medicine,
Год журнала:
2024,
Номер
13(2), С. 592 - 592
Опубликована: Янв. 19, 2024
Transcatheter
aortic
valve
implantation
(TAVI)
is
now
well
established
as
the
treatment
of
choice
for
patients
with
native
stenosis
who
are
high
or
intermediate
risk
surgical
replacement.
Recent
data
has
also
supported
use
TAVI
in
at
low
and
anatomical
subsets
that
were
previously
felt
to
be
contra-indicated
including
bicuspid
valves
regurgitation.
With
advancements
refinements
procedural
techniques,
application
this
technology
been
further
expanded
include
management
degenerated
bioprosthesis.
After
demonstration
feasibility
safety
bioprosthetic
valves,
mitral
tricuspid
well-established
provides
an
attractive
alternative
performing
redo
surgery.
In
review,
we
appraise
latest
clinical
evidence
highlight
considerations
when
utilising
aortic,
prosthesis.
Journal of Zhejiang University (Medical Sciences),
Год журнала:
2025,
Номер
unknown
Опубликована: Апрель 1, 2025
Transcatheter
aortic
valve
replacement
(TAVR)
has
emerged
as
the
first-line
treatment
for
stenosis.
Coronary
obstruction
is
a
severe
complication
of
TAVR,
with
mortality
rates
exceeding
30%.
can
be
classified
acute
or
delayed
based
on
timing
onset,
and
direct
indirect
according
to
underlying
mechanism.
Risk
factors
predicting
coronary
include
small
sinus
Valsalva
diameter,
excessively
long
native
leaflets,
low
height,
sinotubular
junction
height
diameter.
Accurate
preoperative
assessment
these
anatomical
parameters
using
CT
crucial
selecting
appropriate
type,
size,
implantation
depth.
Preventive
technical
strategies
intraoperative
interventional
treatments
(such
"Chimney"
stenting
technique),
leaflet
modification
BASILICA
alignment
annulus
coronaries.
These
techniques
have
demonstrated
significant
efficacy
in
reducing
incidence
associated
mortality.
This
paper
reviews
epidemiology,
classification,
mechanisms
obstruction,
particular
focus
identification,
prevention,
high-risk
patients.
The
aim
highlight
importance
recognizing
managing
risks
during
TAVR
provide
actionable
recommendations
prevention
clinical
practice.
Circulation Cardiovascular Interventions,
Год журнала:
2024,
Номер
17(8)
Опубликована: Авг. 1, 2024
SAPIEN3
(S3)
is
a
ubiquitous
redo-transcatheter
aortic
valve
(TAV)
replacement
alternative
for
degenerated
Evolut
valves,
but
S3
sizing
S3-in-Evolut
remains
unclear.
We
sought
to
compare
the
impact
of
in
vivo
computed
tomography
(CT)-sizing
on
redo-TAV
feasibility
with
traditional
bench-sizing.
EuroIntervention,
Год журнала:
2024,
Номер
20(24), С. e1493 - e1504
Опубликована: Дек. 1, 2024
Transcatheter
aortic
valve
implantation
(TAVI)
is
a
safe
and
effective
procedure
for
the
treatment
of
stenosis.
With
recently
broadened
indications,
there
larger
cohort
patients
likely
to
outlive
their
first
transcatheter
heart
(THV).
This
review
discusses
relevant
lifetime
planning
considerations,
focusing
on
utility
preprocedural
computed
tomography
imaging
help
implanters
future-proof
who
are
valve.
The
initial
priority
optimise
index
by
maximising
THV
haemodynamic
function
durability.
involves
orifice
area,
minimising
risk
new
pacemaker
implantation,
reducing
paravalvular
regurgitation,
preventing
coronary
obstruction
annular
rupture.
In
requiring
second
procedure,
significant
proportion
will
require
TAVI-in-TAVI,
should
consider
key
priorities
redo
including
increased
risks
patient-prosthesis
mismatch
conduction
abnormalities,
promoting
reaccessibility,
sinus
sequestration.
Careful
can
identify
potential
hurdles
as
well
predict
feasibility
outcomes
redo-TAVI,
individualise
care
over
each
patient.
Transcatheter
aortic
valve
replacement
(TAVR)
has
increasingly
become
a
fundamental
approach
for
treating
stenosis
(AVS),
especially
in
high
surgical
risk
patients.
This
case
study
underscores
the
criticality
of
meticulous
procedural
planning
and
precise
selection
patients
with
severe
AVS
compounded
by
obesity.
We
report
patient
who,
after
receiving
26
mm
Edwards
Sapiens
3
valve,
presented
worsening
exertional
dyspnea
declining
indexed
effective
orifice
area
(EOAi).
deterioration
indicated
early
structural
(SVD),
presumably
due
to
patient-prosthesis
mismatch
(PPM).
A
subsequent
valve-in-valve
(ViV)
TAVR
using
29
Medtronic
Evolut
Fx
was
successfully
executed,
leading
notable
improvement
EOAi.
emphasizes
complexities
inherent
choice
sizing
TAVR,
particularly
highlighting
impact
PPM
on
obese
its
potential
precipitate
SVD.
The
further
explores
emerging
strategies
addressing
dysfunctions
via
ViV
interventions,
shedding
light
nuanced
dynamic
nature
management
It
advocates
tailored
treatment
managing
such
intricate
cases,
demonstrating
evolving
landscape
procedures.
EuroIntervention,
Год журнала:
2024,
Номер
20(22), С. 1390 - 1404
Опубликована: Ноя. 1, 2024
Redo-transcatheter
aortic
valve
implantation
(TAVI)
is
the
treatment
of
choice
for
failed
transcatheter
valves.
Currently,
a
SAPIEN
3
(S3)
indicated
redo-TAVI
in
degenerated
CoreValve/Evolut
(CV/EV)
valves
(TAVs)
but
not
well
understood.
European Heart Journal - Case Reports,
Год журнала:
2024,
Номер
8(12)
Опубликована: Ноя. 26, 2024
Computed
tomography
(CT)
assessment
is
the
standard
for
predicting
coronary
obstruction
(CO)
caused
by
sinus
sequestration
(SS)
during
transcatheter
aortic
valve
(TAV)
implantation
in
degenerated
TAV
(TAV-in-TAV)
procedure,
but
it
may
not
always
be
accurate.
This
report
describes
a
prediction
method
CO
using
balloon
valvuloplasty
(BAV)
TAV-in-TAV.
